Why might the CEO of the biotechnology firm discussed in Question 7 be concerned about the firm being undervalued? Would the CEO be equally concerned if the stock were overvalued? Do you believe that the CEO would attempt to correct the market’s perception in this overvaluation case? How would you react to company concern about market under- or overvaluation if you were the firm’s auditor? Or if you were a member of the audit committee?